Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SK pseudogene 218 (RN7SKP218) is annotated as a pseudogene derived from the 7SK small nuclear RNA gene, which participates in regulation of transcription elongation through sequestration of P-TEFb in its canonical, functional form[1][2][3]. However, pseudogenes like RN7SKP218 do not code for functional RNA and are generally considered non-functional remnants of gene duplication or retrotransposition. They are not regarded as therapeutic targets, do not encode proteins or enzymes, and lack evidence for any impact on cell biology, disease, or drug response[3][5]. All established literature and biological relevance pertain to the parental RN7SK gene and its functional RNA, not to RN7SKP218 or other pseudogenes in this family[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RN7SK pseudogene 218 (RN7SKP218).